Innovative ETFs ChannelHealthcare, Biotech ETFs Plunge on Mounting Political PressuresBy Max ChenApril 18, 2019
Innovative ETFs ChannelHealthcare ETFs Lag the Broader Market Amidst Regulation ScareBy Max ChenApril 15, 2019
Relative Value ChannelWill Tighter Government Regulation Test Health Care ETFs?By Ben HernandezApril 15, 2019
Innovative ETFs ChannelHealthcare ETFs Deteriorate on Congress’ Threats to Drug PricesBy Max ChenApril 12, 2019
Equity ETF ChannelA Targeted ETF to Capture M&A, Consolidation in the Biotech SpaceBy Max ChenApril 10, 2019
Leveraged & Inverse ChannelHealth Care ETFs Get a Boost From Latest Jobs ReportBy Ben HernandezApril 6, 2019
Relative Value ChannelWarren Buffett on Overhauling Health Care: “There’s Enormous Resistance to Change”By Ben HernandezMarch 18, 2019
Innovative ETFs ChannelHealthcare, Biotech ETFs XLV and XBI Slide on FDA’s Uncertain OutlookBy Max ChenMarch 6, 2019
Innovative ETFs ChannelA Specialty Biotech ETF Strengthens on Optimism Over CRISPR AdvancementsBy Max ChenMarch 1, 2019
Innovative ETFs ChannelPharmaceutical ETFs Break Out on Horizon Pharma’s Positive Drug ResultsBy Max ChenFebruary 28, 2019
Equity ETF ChannelSpark Therapeutics Acquisition Sparks Rally in Biotechnology ETFsBy Max ChenFebruary 25, 2019
Innovative ETFs ChannelSpecialized Biotech ETF Rallies on MacroGenics Positive Trial ResultsBy Max ChenFebruary 6, 2019
Core ETF ChannelHealthcare ETFs Slip After Abbot Lab’s Revenue Miss, Weak OutlookBy Max ChenJanuary 23, 2019
Leveraged & Inverse ChannelRising U.S. Health Care Spending a Boon to this Leveraged ETFBy Ben HernandezJanuary 8, 2019
